Search results
Showing 1 to 16 of 16 results for amyloidosis
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Find out more about NICE's new proportionate approach to technology appraisals
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)
Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.
Diabetes in pregnancy: management from preconception to the postnatal period (NG3)
This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
This guideline covers assessment, treatment, monitoring and inpatient care for children, young people and adults with eating disorders. It aims to improve the care people receive by detailing the most effective treatments for anorexia nervosa, binge eating disorder and bulimia nervosa.
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666
Awaiting development [GID-TA11182] Expected publication date: TBC
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy TS ID 11904
Awaiting development [GID-TA11415] Expected publication date: TBC
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]
In development [GID-TA11392] Expected publication date: 14 August 2024
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]
In development [GID-TA11389] Expected publication date: 12 June 2024